PA8769901A1 - Formulacion de pastillas de liberacion sostenida de antagonistas y agonistas de piperazina-piperidina del receptor 5-ht1a que tienen disolucion intestinal mejorada - Google Patents

Formulacion de pastillas de liberacion sostenida de antagonistas y agonistas de piperazina-piperidina del receptor 5-ht1a que tienen disolucion intestinal mejorada

Info

Publication number
PA8769901A1
PA8769901A1 PA20088769901A PA8769901A PA8769901A1 PA 8769901 A1 PA8769901 A1 PA 8769901A1 PA 20088769901 A PA20088769901 A PA 20088769901A PA 8769901 A PA8769901 A PA 8769901A PA 8769901 A1 PA8769901 A1 PA 8769901A1
Authority
PA
Panama
Prior art keywords
piperazine
piperidine
sustained release
agenists
antigonists
Prior art date
Application number
PA20088769901A
Other languages
English (en)
Inventor
Ghosh Krishnendu
Wen Hong
Nagi Arwinder
Goolcharran Chimanlall
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PA8769901A1 publication Critical patent/PA8769901A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A FORMULACIONES DE PASTILLAS DE LIBERACION SOSTENIDA DE COMPUESTOS DE PIPERAZINA-PIPERIDINA, LOS CUALES PUEDEN SER UTILES EN EL TRATAMIENTO DE TRASTORNOS DEL SISTEMA NERVIOSO CENTRAL; A PROCESOS PARA SU PREPARACION; Y PARA METODOS DE SU USO.
PA20088769901A 2007-02-16 2008-02-15 Formulacion de pastillas de liberacion sostenida de antagonistas y agonistas de piperazina-piperidina del receptor 5-ht1a que tienen disolucion intestinal mejorada PA8769901A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90191207P 2007-02-16 2007-02-16

Publications (1)

Publication Number Publication Date
PA8769901A1 true PA8769901A1 (es) 2008-11-19

Family

ID=39596364

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20088769901A PA8769901A1 (es) 2007-02-16 2008-02-15 Formulacion de pastillas de liberacion sostenida de antagonistas y agonistas de piperazina-piperidina del receptor 5-ht1a que tienen disolucion intestinal mejorada

Country Status (5)

Country Link
US (1) US20080226714A1 (es)
AR (1) AR065376A1 (es)
PA (1) PA8769901A1 (es)
TW (1) TW200846032A (es)
WO (1) WO2008101139A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115710224A (zh) * 2020-06-28 2023-02-24 海创药业股份有限公司 一种喹啉类化合物晶型及其制备方法
AU2021464980A1 (en) * 2021-09-17 2024-05-02 Hinova Pharmaceuticals Inc. Quinoline compound sustained-release tablet and preparation method therefor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7276603B2 (en) * 2003-05-02 2007-10-02 Wyeth Benzofuranyl-and benzothienyl-piperazinyl quinolines and methods of their use
US20050215561A1 (en) * 2004-03-19 2005-09-29 Krishnendu Ghosh Pharmaceutical dosage forms and compositions
TWI391387B (zh) * 2004-05-12 2013-04-01 Eisai R&D Man Co Ltd 具有哌啶環之吲哚衍生物
TW200800959A (en) * 2005-06-10 2008-01-01 Wyeth Corp Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
TW200808741A (en) * 2006-06-09 2008-02-16 Wyeth Corp 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts
TW200808740A (en) * 2006-06-09 2008-02-16 Wyeth Corp Succinate salts of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline and crystalline forms thereof
US20080199518A1 (en) * 2006-11-28 2008-08-21 Wyeth Controlled-release formulation of piperazine-piperidine antagonists and agonists of the 5-HT1A receptor having enhanced intestinal dissolution

Also Published As

Publication number Publication date
WO2008101139A1 (en) 2008-08-21
AR065376A1 (es) 2009-06-03
US20080226714A1 (en) 2008-09-18
TW200846032A (en) 2008-12-01

Similar Documents

Publication Publication Date Title
UY31570A1 (es) Derivados de oxadiazol agonistas del receptor s1p1. composiciones farmacéuticas que lo comprenden y procedimientos de preparacion de los mismos
PA8770101A1 (es) Amidas de 4-aril-1,4-dihidro-1, 6-naftiridina sustituidas y su uso
BRPI0821732A2 (pt) Formulações de liberação controlada , forma de dosagem sólida, e, uso da formulação de liberação controlada
CL2008002893A1 (es) Compuestos derivados de n-fenil-(piridin-3-il) acetamida sustituidas; composicion farmaceutica; procedimiento de preparacion; y su uso para prevenir o tratar el cancer.
GT200800250A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
HN2010002030A (es) Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
NI201000044A (es) Bromhidrato de bupropión y aplicaciones terapéuticas
BRPI0911988A2 (pt) micelas para liberação intracelular de agentes terapêuticos.
CL2013001338A1 (es) Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih.
CR20110596A (es) Composiciones sublinguales de dexmedetomidina y métodos de uso de ellas
DOP2013000007A (es) Pirimidinadas y triazinas condensadas y su uso
CR11731A (es) Composiciones y procedimientos para su preparación y uso
BRPI0818906A2 (pt) Formulação sólida de liberação rápida, preparação e uso da mesma
ATE530170T1 (de) Paliperidonformulierung mit verzögerter freisetzung
PA8846101A1 (es) Anticuerpos del receptor ii anti-tgf-beta
CL2008000641A1 (es) Compuestos derivados de amidas sustituidas; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento del insomnio, disfuncion sexual, esquizofrenia, entre otras enferme
CL2011002467A1 (es) Compuestos derivados de 6-(3-aza-biciclo[3.1.0]hex-3-il)-2-fenilpirimidinas, antagonistas del receptor p2y 12; composicion farmaceutica que los comprende; y su uso en el tratamiento de trastornos oclusivos. pct fase nacional.
GT201000179A (es) "antagonistas del receptor mineralcorticoide y metodos de uso"
CL2011001331A1 (es) Clorhidrato de nalmefeno dihidratado; métodos para su preparación; composición farmacéutica que lo comprende; y uso para el tratamiento del alcoholismo.
CR20120549A (es) Composiciones farmacèuticas que comprenden hidromorfona y naloxona
UY31922A (es) Compuestos
DOP2012000279A (es) Composiciones farmaceuticas que comprenden hidromorfona y naloxona
NI201000015A (es) Bromhidrato de bupropión y aplicaciones terapéuticas
UY32734A (es) Compuestos agonistas del receptor esfingosina 1-fosfato
TN2009000510A1 (en) Extended release formulation of nevirapine